Researcher

Dave Keng Boon Wee is the Principal Investigator of the RNA Modulation for Novel Therapeutics Lab at the A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) and also serves as Cluster Chair for the National Initiative of RNA Biology and Applications (NIRBA), Singapore. He holds a degree in chemical engineering from the National University of Singapore (NUS), where he also self-taught computer science.

After co-founding a pioneering cloud computing startup in 2000, Wee joined ST Technologies to lead the development of a real-time command-and-control artillery system. His growing interest in bioinformatics led him to pursue MSc and PhD degrees in the field at NUS with the support of A*STAR scholarships, earning recognition such as the Human Genome Organisation’s Outstanding Research for Young Scientists award.

Driven by a passion for invention and a systems-engineering mindset, Wee focuses on understanding and rationally perturbing complex biological systems through mechanistic modelling and computational analyses. He works closely with experimental collaborators and has contributed technologies to over 50 projects across 28 labs worldwide. In 2018, he co-founded ImmuNOA, an A*STAR spinoff developing next-generation cell immunotherapies, which was acquired by LionTCR in 2024.